| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 11/12/2003 | EP1051187B1 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway |
| 11/12/2003 | EP0994904B1 Amino acid sequences for therapeutical and prophylactic applications to diseases due to clostridium difficile toxins |
| 11/12/2003 | EP0817650B1 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| 11/12/2003 | EP0742829B1 Expression of heterologous proteins in attenuated bacteria using the htra-promoters |
| 11/12/2003 | CN1455866A Detection of infectious agents using antigen mmics |
| 11/12/2003 | CN1455816A Rescue of canine distemper virus from CDNA |
| 11/12/2003 | CN1455815A Malaria plasmodium antigen polypeptide SE36, method of purifying same and vaccine and diagnosis with use of obtained antigen |
| 11/12/2003 | CN1455813A Human myeloma cell line |
| 11/12/2003 | CN1455781A Discrimination between GnRH-Ôàáand GnRH-Ôàí" |
| 11/12/2003 | CN1455680A MUCl extracellular domain and cancer treatment compositions and methods derived therefrom |
| 11/12/2003 | CN1455674A Use of sheep's parapoxvirus bacterial strain for preparing anti-virus medicines and anti-cancer medicine |
| 11/12/2003 | CN1454901A Gynaecological anti-infective specificity IgY and its combined preparation |
| 11/12/2003 | CN1454668A Anti-hepatitis-B-virus therapeutic vaccine and its adjuvant |
| 11/12/2003 | CN1127352C CCK antibodies used to improve feed efficiency |
| 11/12/2003 | CN1127351C Method for inducing antigen-specific T cell tolerance |
| 11/11/2003 | USRE38313 4 immunoglobulin type extracellular domains having arginine residues substituted by glutamic acid; immunosuppressants; preventing specific binding to major histocompatibility complex |
| 11/11/2003 | US6646108 Process for isolating IgG and IgA |
| 11/11/2003 | US6645962 Process of using prodigiosin as an immunosuppressive |
| 11/11/2003 | US6645935 Synthesis of glycoconjugates of the lewis Y epitope and uses thereof |
| 11/11/2003 | US6645933 Polypeptide that binds extracellular domain of human Flt4 receptor tyrosine kinase; genetic engineering; endothelial cell growth factors and genes |
| 11/11/2003 | US6645753 Polynucleotides; antisense agents; MAP-kinases; nucleotide sequences; use of polypeptides to identify agents modulating signal transduction leading to cell proliferation, differen-tiation, survival and treatment of such conditions (cancer) |
| 11/11/2003 | US6645740 Nucleic acids encodings equine GM-CSF |
| 11/11/2003 | US6645504 Certain antigens (called "bystander antigens" and defined below) causes T-cells to be elicited that in turn suppress cells that contribute to immune attack of the organ or tissue involved in an autoimmune disease |
| 11/11/2003 | US6645503 Eliciting a cross reactive immune response against heterologous strains of the gram negative bacteria; vaccines; comprises the inner core and lipid A portions of the lipopolysaccharide |
| 11/11/2003 | US6645501 Anti-pathogen system and methods of use thereof |
| 11/11/2003 | US6645500 Method for down-regulating osteoprotegerin ligand activity |
| 11/11/2003 | US6645496 Treating cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretion by administering Botulinum toxin type A |
| 11/11/2003 | US6645495 Compositions of saponin adjuvants and excipients |
| 11/11/2003 | US6645494 An antibody, or a binding fragment thereof, specific for human CD40L antigen conjugated to a Type I ribosome inactivating protein |
| 11/11/2003 | US6645493 Composition containing anti-MIF antibody |
| 11/11/2003 | US6645492 For diagnosis and therapy of susceptibility to atopic allergy, asthma |
| 11/11/2003 | US6645486 Administering conjugate of interleukin 9 and carrier such as ovalbumin; induce production of IL-9 specific antibodies to bind to and reduce pathological condition such as asthma, mast cell activation, eosinophilia, allograft rejection |
| 11/11/2003 | US6645484 Endothelial cell transmembrane tyrosine kinase ligand |
| 11/11/2003 | US6645465 Diagnosing cancer in humans; obtain sample, detect annexin protein in sample, amplified concentration of annexins indicates cancer |
| 11/11/2003 | CA2259594C Subunit respiratory syncytial virus vaccine preparation |
| 11/11/2003 | CA2210294C Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens |
| 11/06/2003 | WO2003091734A1 Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases |
| 11/06/2003 | WO2003091456A1 A dna enzyme to inhibit plasminogen activator inhibitor-1 |
| 11/06/2003 | WO2003091438A1 Genetic vaccine against rna-viral infections |
| 11/06/2003 | WO2003091437A1 Chimeric camp factors for vaccination against streptococcus infection |
| 11/06/2003 | WO2003091414A2 Adipocyte complement related protein zacrp8 |
| 11/06/2003 | WO2003091401A2 Multi plasmid system for the production of influenza virus |
| 11/06/2003 | WO2003091395A2 Inhibition of immune complex formation |
| 11/06/2003 | WO2003091387A2 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 11/06/2003 | WO2003091383A2 Epha2 antigen t epitopes |
| 11/06/2003 | WO2003091279A2 COMBINATION VACCINES INCLUDING IMMUNOGENIC GapC AND CAMP FACTOR POLYPEPTIDES |
| 11/06/2003 | WO2003090781A1 Methods and devices for targeting a site in a mammal and for removing species from a mammal |
| 11/06/2003 | WO2003090778A2 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 11/06/2003 | WO2003090776A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 11/06/2003 | WO2003090772A1 Method for treating anxiety and mood disorders in older subjects |
| 11/06/2003 | WO2003090733A1 Inhibition of platelet aggregation |
| 11/06/2003 | WO2003090687A2 Using heat shock proteins to increase immune response |
| 11/06/2003 | WO2003090685A2 Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses |
| 11/06/2003 | WO2003090676A2 Immunogenic agent therapy using plasmapheresis or exchange transfusion |
| 11/06/2003 | WO2003090675A2 Methods and compositions useful for treating prostate cancer |
| 11/06/2003 | WO2003090667A2 Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus |
| 11/06/2003 | WO2003090512A2 Regeneration of endogenous myocardial tissue by induction of neovascularization |
| 11/06/2003 | WO2003080114A3 Imidazoquinoline adjuvants for vaccines |
| 11/06/2003 | WO2003080112A3 Imidazoquinolineamines as adjuvants in hiv dna vaccination |
| 11/06/2003 | WO2003054541A3 Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 11/06/2003 | WO2003052124A3 Screening method for agents useful in treating diabetes |
| 11/06/2003 | WO2003049766A3 Method of purifying hepatitis a virus particles and vaccine preparation |
| 11/06/2003 | WO2003049694A3 Methods of therapy for non-hodgkin's lymphoma |
| 11/06/2003 | WO2003049670A3 Adjuvant formulations for bacterial and virus vaccines and method of making same |
| 11/06/2003 | WO2003048327A3 Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection |
| 11/06/2003 | WO2003035004A3 Immunotherapy for reversing immune suppression |
| 11/06/2003 | WO2003031939A3 Protein modification and maintenance molecules |
| 11/06/2003 | WO2003030934A3 Cpg formulations and related methods |
| 11/06/2003 | WO2003027263A3 Proteins associated with cell growth, differentiation, and death |
| 11/06/2003 | WO2003024393A3 Autologous t-cell vaccines materials and method |
| 11/06/2003 | WO2003023021A3 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture |
| 11/06/2003 | WO2003016354A3 Recombinant anti-plasmodium falciparum antibodies |
| 11/06/2003 | WO2003011878A3 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| 11/06/2003 | WO2003011335A3 Polyvalent vaccine against diseases caused by papilloma viruses, method for the production and the use thereof |
| 11/06/2003 | WO2003006506A3 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 11/06/2003 | WO2003005880A3 Replikin peptides and uses thereof |
| 11/06/2003 | WO2003003906A3 Diagnostic and screening methods for bladder cancer |
| 11/06/2003 | WO2002094845A3 Method for stabilising of nucleic acids |
| 11/06/2003 | WO2002094313A3 Vaccine composition |
| 11/06/2003 | WO2002092773A3 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 11/06/2003 | WO2002083903A3 West nile virus epitopes and uses thereof |
| 11/06/2003 | WO2002083854A9 Antibodies to vla-1 |
| 11/06/2003 | WO2002083711A3 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies |
| 11/06/2003 | WO2002079242A3 Adp-ribosylating bacterial toxins |
| 11/06/2003 | WO2002076482B1 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS |
| 11/06/2003 | WO2002072600A3 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| 11/06/2003 | WO2002070657A8 93870, a human g-protein coupled receptor and uses therefor |
| 11/06/2003 | WO2002066649A8 ANTI-INTERFERON-α ANTIBODIES |
| 11/06/2003 | WO2002062945A3 Compositions and methods relating to lung specific genes and proteins |
| 11/06/2003 | WO2002061105A3 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 11/06/2003 | WO2002061070A8 Environmentally regulated genes, involved in the virulence of streptococcus suis |
| 11/06/2003 | WO2002060491A3 Stabilization of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 11/06/2003 | WO2002059312A3 Cell adhesion proteins |
| 11/06/2003 | WO2002053742A3 Proteins and nucleic acids encoding same |
| 11/06/2003 | WO2002030257A3 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 11/06/2003 | WO2002026785A3 Epitopes of virus hepatitis c specifically cd4+ t lymphocytes |
| 11/06/2003 | WO2002024883A3 Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions |
| 11/06/2003 | WO2002004952A3 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 11/06/2003 | WO2001085773A8 Luxo-sigma54 interactions and methods of use |
| 11/06/2003 | US20030208058 B7-like polypeptides and polynucleotides |